Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: A prospective survey.
antithrombotic
benign prostatic hyperplasia
diode laser
Journal
Asian journal of endoscopic surgery
ISSN: 1758-5910
Titre abrégé: Asian J Endosc Surg
Pays: Japan
ID NLM: 101506753
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
23
02
2022
received:
24
01
2022
accepted:
09
03
2022
pubmed:
22
3
2022
medline:
7
7
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
To prospectively clarify whether endoscopic contact laser vaporization of the prostate (CVP) can be safely performed even in patients undergoing antithrombotic therapy. Fifty-five patients treated with CVP were enrolled. Patients were assigned to: (i) the antithrombotic therapy group (n = 21, 38%); or (ii) control group without antithrombotic therapy (n = 34, 62%). All patients in the antithrombotic therapy group continued all antithrombotic agents during the perioperative period and thereafter. No difference was noted in patient background between the two groups. In primary endpoints, decreases in the postoperative hemoglobin level were remarkable in the antithrombotic therapy group, while no serious effects were noted in either group. The control and antithrombotic therapy groups did not show a significant difference in the occurrence of catheter obstruction due to blood clots or serious hematuria following catheter removal. During follow-up, transurethral coagulation for hemostasis was needed only in the antithrombotic therapy group, with a frequency of transurethral coagulation of up to 14%. In secondary endpoints, no difference in the occurrence of perioperative or late-onset complications after surgery was noted between the two groups. Finally, no difference was noted in improvements in the International Prostate Symptom Score (IPSS), IPSS quality of life score, overactive bladder symptom score, maximum flow rate, or post-voiding residual urine volume between the two groups throughout the follow-up period. CVP can be performed safely and effectively in patients undergoing continuous antithrombotic therapy. However, the possibility of secondary bleeding after discharge in a subset of patients, such as those undergoing antithrombotic therapy, may be noted.
Substances chimiques
Fibrinolytic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
585-590Informations de copyright
© 2022 Asia Endosurgery Task Force and Japan Society of Endoscopic Surgery and John Wiley & Sons Australia, Ltd.
Références
Mamoulakis C, Skolarikos A, Schulze M, et al. Results from an international multicentre double-blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate. BJU Int. 2012;109(2):240-248.
Chen YB, Chen Q, Wang Z, et al. A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. J Urol. 2013;189(1):217-222.
Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Circulation. 2015;131(5):488-494.
Shaker HS, Shoeb MS, Yassin MM, Shaker SH. Quartz head contact laser fiber: a novel fiber for laser ablation of the prostate using the 980 nm high power diode laser. J Urol. 2012;187(2):575-579.
Wendt-Nordahl G, Huckele S, Honeck P, et al. 980-nm diode laser: a novel laser technology for vaporization of the prostate. Eur Urol. 2007;52(6):1723-1728.
Keoghane SR, Lawrence KC, Gray AM, et al. A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up. BJU Int. 2000;85(1):74-78.
Mithani MH, Khalid SE, Khan SA, et al. Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: a prospective study. Investig Clin Urol. 2018;59(6):392-398.
Homma Y, Gotoh M, Kawauchi A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol. 2017;24(10):716-729.
Shaker H, Alokda A, Mahmoud H. The twister laser fiber degradation and tissue ablation capability during 980-nm high-power diode laser ablation of the prostate. A randomized study versus the standard side-firing fiber. Lasers Med Sci. 2012;27(5):959-963.
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43(3):289-297.
Kuntz RM. Laser treatment of benign prostatic hyperplasia. World J Urol. 2007;25(3):241-247.
Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018;97(51):e13360.
Kobayashi T, Seki N, Song YH, Dejima T. GreenLight HPS laser 120 W vs diode laser 300 W vaporization of the prostate for the treatment of benign prostatic hyperplasia in Japanese patients: a prospective, single-center, randomized clinical trial. Low Urin Tract Symptoms. 2021;13(1):31-37.
Yee CH, Wong JH, Chiu PK, et al. Secondary hemorrhage after bipolar transurethral resection and vaporization of prostate. Urol Ann. 2016;8(4):458-463.